Catch up on the top radiology content of the past week.
|Articles|August 20, 1997
ADAC's Lowe passes CEO title to Eckert
ADAC Laboratories has added CEO to Andrew Eckert's list of titles, which already includes president and COO. Giving up the CEO mantle is David Lowe, who will remain chairman of the Milpitas, CA, nuclear medicine vendor. ADAC said the transition was part
Advertisement
ADAC Laboratories has added CEO to Andrew Eckert's list of titles, which already includes president and COO. Giving up the CEO mantle is David Lowe, who will remain chairman of the Milpitas, CA, nuclear medicine vendor. ADAC said the transition was part of a long-planned management development strategy, and that Lowe will continue to develop the company's strategic and operating plans.
In other ADAC news, the company signed an agreement to provide multivendor service and support of gamma cameras to customers in the asset management program of independent service organization COHR. The agreement will add over 75 gamma cameras to ADAC's multivendor service effort, which ADAC began in 1995 with the acquisition of JD Technical Services (SCAN 12/13/95).
Advertisement
Related to this article
While a new article raises provocative questions about the capability of photon-counting CT (PCCT) to perhaps replace diagnostic ICA, the real revolution with this modality is going beyond stenosis measurement to a renewed focus on the disease of atherosclerosis.
The use of adjunctive CT bone reading software in women with breast cancer detected between 8 to 22 percent more metastatic lesions for reviewing radiologists and reduced CT interpretation time by 50 percent or more, according to a new study.
Catch up on the top radiology content of the past week.
Catch up on the top radiology content of the past week.
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
2
Can MRI-Based AI Have an Impact in Reducing Unnecessary Prostate Biopsies?
3
The Reading Room Podcast: A Closer Look at New Research on 177Lu-Edotreotide for Treating GEP-NETs
4
How AI, Theranostics and More Empowered Patients Have Led to Significant Changes in Radiology
5